Isotretinoin

CAS 4759-48-2 10 current records 4 historicalSmall Molecule

Who holds supplier records for Isotretinoin? 10 organisations hold a current record for Isotretinoin: an active US FDA Type II Drug Master File or a CEP. A further 4 organisations have only historical (inactive) DMF filings. 7 of them hold a valid EU Certificate of Suitability. Recorded organisation countries for current records: India (4), China (2), Switzerland (1), Italy (1) and 1 other country (1); not recorded for 1.

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records

Cite as: PharmaTek, “Isotretinoin: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/isotretinoin

Reading the evidence

  • 10 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • 5 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

  • US product patents listed

    The latest patent listed in the FDA Orange Book for an approved product containing Isotretinoin expires 4 Aug 2035. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.

Current records (10)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Isotretinoin. Country is the organisation's recorded country, not necessarily the manufacturing site.

India4China2Switzerland1Italy1Germany1Country not recorded for 1
Need Isotretinoin sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

Valid CEP holder entries (7)

Certificates of Suitability on the EDQM register for Isotretinoin, including the salts, esters and hydrates the register lists separately; each row shows the substance as named on the certificate. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer. 12 certificates in total, including withdrawn, expired, suspended and repeat certificates.

HolderCountryCertificateIssuedEU GMP at holder's address
SUN PHARMACEUTICAL INDUSTRIES LIMITED MumbaiIN
CEP 2002-011 - Rev 07
Isotretinoin
May 2026—
HETERO DRUGS LIMITED HyderabadIN
CEP 2022-205 - Rev 01
Isotretinoin
Jul 2024—
CHONGQING HUAPONT PHARMACEUTICAL CO., LTD. ChongqingCN
CEP 2018-219 - Rev 01
Isotretinoin, Process 2
Dec 2023—
SIEGFRIED PHARMACHEMIKALIEN MINDEN GMBH MindenDE
R1-CEP 1999-068 - Rev 07
Isotretinoin
Mar 2023—
OLON S.P.A. RodanoIT
R1-CEP 1996-082 - Rev 12
Isotretinoin
Apr 2022—
HAS HEALTHCARE ADVANCED SYNTHESIS SA BiascaCH
R1-CEP 2004-281 - Rev 01
Isotretinoin
Mar 2022—
SHANGHAI NEW HUALIAN PHARMACEUTICAL CO., LTD. ShanghaiCN
R1-CEP 2008-231 - Rev 02
Isotretinoin
Jun 2020—

The GMP column shows the most recent EU GMP certificate issued for the same address as the holder, joined on the EMA location identifier printed on both documents (EudraGMDP, re-read about once a quarter; withdrawn certificates are excluded). A dash means no certificate carries that identifier, not that the site is uninspected. The holder's address is not necessarily where the substance is made.

Certification Online Database. European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, (2026), URL: https://extranet.edqm.eu/publications/recherches_CEP.shtml. Accessed 16 Nov 2026. Reproduced with permission and unaltered. The EDQM and the Council of Europe accept no liability for any consequence arising from its use.

Historical records (4)

Organisations whose Type II DMFs for Isotretinoin are no longer active. These show a past filing, not current supply.

Show all 4 historical records

US product patents and exclusivity

The FDA Orange Book lists patents and exclusivities for specific approved products (59 listed products contain Isotretinoin). The latest listed patent expires 4 Aug 2035. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.

Overview

Isotretinoin is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL547).

Chemical identity

IUPAC name
(2Z,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid
Canonical SMILES
CC1=C(C(CCC1)(C)C)/C=C/C(=C/C=C/C(=C\C(=O)O)/C)/C
InChIKey
SHGAZHPCJJPHSC-XFYACQKRSA-N
Synonyms
13 cis-retinoic acid, 13-cis-retinoic acid, Absorica, Absorica ld, Accutane, Amnesteem, Claravis, Isotretinoin, Isotretinoina, Isotretinoine, Isotrex, Myorisan

Pharmacologic class

As the US FDA states it for this active substance on product listings.

Established pharmacologic class
Retinoid
Chemical structure
Retinoids

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Isotretinoin?

10 organisations hold an active US FDA Type II Drug Master File or a CEP for Isotretinoin: CHONGQING HUAPONT PHARMACEUTICAL CO LTD, HAS Healthcare Advanced Synthesis SA (Switzerland), Hetero Drugs Limited (India), OLON SPA (Italy), SIEGFRIED PHARMACHEMIKALIEN MINDEN GMBH (Germany), Sun Pharmaceutical Industries Limited (India), APIONEX PHARMA PVT LTD (India) and BIOPHORE INDIA PHARMACEUTICALS PRIVATE LIMITED (India), and 2 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Isotretinoin Drug Master Files are active?

CHONGQING HUAPONT PHARMACEUTICAL CO LTD (DMF 34510, 21653), HAS Healthcare Advanced Synthesis SA (DMF 19918), Hetero Drugs Limited (DMF 36857), OLON SPA (DMF 7485), SIEGFRIED PHARMACHEMIKALIEN MINDEN GMBH (DMF 4676), Sun Pharmaceutical Industries Limited (DMF 15169, 32517), APIONEX PHARMA PVT LTD (DMF 44474) and BIOPHORE INDIA PHARMACEUTICALS PRIVATE LIMITED (DMF 27484) and 1 more. The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

What do the historical Isotretinoin records mean?

4 organisations have only inactive Type II DMFs for Isotretinoin. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.

Does Isotretinoin have a European Certificate of Suitability?

Yes. 7 organisations hold a valid CEP for Isotretinoin on the EDQM register, including SUN PHARMACEUTICAL INDUSTRIES LIMITED Mumbai (IN), HETERO DRUGS LIMITED Hyderabad (IN), CHONGQING HUAPONT PHARMACEUTICAL CO., LTD. Chongqing (CN), SIEGFRIED PHARMACHEMIKALIEN MINDEN GMBH Minden (DE), OLON S.P.A. Rodano (IT) and HAS HEALTHCARE ADVANCED SYNTHESIS SA Biasca (CH) and 1 more. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.

Does the FDA Orange Book list patents for products containing Isotretinoin?

Yes. The latest patent listed for an approved US product containing Isotretinoin expires 4 Aug 2035, across 59 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.

How do I qualify a Isotretinoin supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Isotretinoin?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.